Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

91 through 100 of 311

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Do sugared beverages increase the risk of early-onset colorectal cancer?

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Healthy people with an average colorectal cancer risk

A study of female nurses in the U.S. suggests that a high intake of sugar-sweetened beverages may increase the risk of colorectal cancer before age 50. However, researchers saw few early-onset colorectal cancer cases which limited the findings. (posted 9/21/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Article : Transgender peoples' perspectives of being diagnosed with gender-associated cancer

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: transgender people

An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : Pembrolizumab receives FDA approval for people with early-stage, triple-negative breast cancer

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with early-stage, triple-negative breast cancer who have a high risk for recurrence

The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence.  This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Drinking coffee or tea may improve survival after breast cancer

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with breast cancer who drink coffee or tea.

In a study of 8,900 women with stage 1, 2 or 3 breast cancer, those who drank coffee survived longer after a breast cancer diagnosis than those who did not drink coffee. Both coffee and tea were linked to improved survival from any cause. Several factors were linked to greater coffee or tea consumption, so this finding must be taken with some caution. However, breast cancer survivors who are regular coffee or tea drinkers may find this research reassuring.  (posted 8/31/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Frequency of inherited mutations linked to breast cancer are similar in Black and white women

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Non-Hispanic Black and white women with breast cancer

The CARRIERS study looked at the rate of inherited mutations in women with and without breast cancer. In an extension of the CARRIERS study, researchers found no difference in the frequency of inherited mutations in breast cancer genes among Black and white women with breast cancer. A few individual genes differed in frequency: BRCA2 and PALB2 mutations were seen more often in Black women, while CHEK2 mutations were seen less often. Researchers concluded that race should not be used to determine who is referred for genetic testing. (posted 8/13/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Update : Breast cancer disparities in Black Americans

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Most relevant for: Black women in the US

The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this review, we highlight findings on the burden of breast cancer in Black women. (posted 8/5/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Article : Overview of pancreatic cancer treatment options

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People with pancreatic cancer

This review looks at current strategies for pancreatic cancer care and potential future therapies. (posted 7/28/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Test score may predict which prostate cancer patients can safely skip combined therapy

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Men with advanced prostate cancer

This study shows that a test score that estimates the aggressiveness of a person’s prostate cancer may also identify the best treatment for patients. (posted 7/9/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Cancer risks of people with inherited PALB2 mutations

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: people with inherited PALB2 mutations

In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)

Este artículo está disponible en español.

Read More